Lineage Cell Therapeutics Inc. (LCTX)

The total asset value of Lineage Cell Therapeutics Inc. (LCTX) stood at $ 130 Mln as on 31-Mar-23

The share price of Lineage Cell Therapeutics Inc. (LCTX) is $1.180000 (NYSE) as of 25-Sep-2023 16:10 EDT. Lineage Cell Therapeutics Inc. (LCTX) has given a return of 8.26% in the last 3 years.

Lineage Cell Therapeutics Inc. (LCTX) has a market capitalisation of $ 225 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Lineage Cell Therapeutics Inc. (LCTX) is 2.78 times as on 02-Jun-2023, a -0.01% premium to its peers’ median range of 2.82 times.

Since, TTM earnings of Lineage Cell Therapeutics Inc. (LCTX) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lineage Cell Therapeutics Inc. (LCTX) and enter the required number of quantities and click on buy to purchase the shares of Lineage Cell Therapeutics Inc. (LCTX).

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

The CEO & director of Mr. Brian M. Culley M.A., M.B.A.. is Lineage Cell Therapeutics Inc. (LCTX), and CFO & Sr. VP is Mr. George A. Samuel III, J.D..

There is no promoter pledging in Lineage Cell Therapeutics Inc. (LCTX).

Some of the close peers are:

No, TTM profit after tax of Lineage Cell Therapeutics Inc. (LCTX) was $-24 Mln.